Table 3.

Comparison of contemporary hypertension cohorts in Sweden

	Current study	HyperQ18	SPCCD26	QregPV41
Year of survey	2013	2002–2005	2007–2008	2014
Patients, No.	292 623	6537	62 407	223 663
Men/women, %	47/53	48/52	44/56	48/53
Age (range), y	68 ± 13 (20–109)	66 ± 12–	69 ± 13 (37–106)	69 ± 12 (15–113)
Systolic/diastolic blood pressure, mm Hg	–	147 ± 17/82 ± 9	143 ± 18/80 ± 10	136 ± 16/79 ± 13
Atrial fibrillation/flutter, %	11	–	8	–
Ischemic heart disease, %	14	–	15	15
Heart failure, %	8	–	8	–
Diabetes mellitus, %	21	22	24	22
Cerebrovascular disease, %	6	–	8	–
No cardiovascular disease, %	59	–	56	–
Data on medicines used	Dispensed	Prescribed	Prescribed	Dispensed
ACEIs, women, %	27	18	32	25
ACEIs, men, %	36	27	44	35
ARBs, women, %	30	34	23	30
ARBs, men, %	29	35	23	30
ACEIs and/or ARBs, women, %	57	51	55	54
ACEIs and/or ARBs, men, %	65	62	67	64
CCBs, women, %	29	26	30	32
CCBs, men, %	34	34	35	31
β‐Blockers, women, %	39	54	51	41
β‐Blockers, men, %	38	51	49	39
Diuretics, women, %	38	64	48	37
Diuretics, men, %	32	48	37	32

Contemporary Swedish cohort studies on patients with hypertension reporting on 10 000 or more patients from 2000 or later. Data are presented as mean values ± standard deviations or proportions, as appropriate. Cerebrovascular disease includes transient ischemic attack and stroke. No cardiovascular disease is defined as patients with hypertension with no ischemic heart disease, atrial fibrillation, congestive heart failure, or cerebrovascular disease. Abbreviations: ACEIs, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers; SPCCD, Swedish Primary Care Cardiovascular Database.